Evidence map›Paper›PMID 42183839›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

PGK1 Suppresses CD8

Xi Liu, Jianpeng Liu, Zhihao Zhang, Xizhi Yu, Junjie Qian, Limin Ding, Qinchuan Wu, Zhe Yang, Xing-Yu Luo, Xinjiang Ding and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Xi LiuDivision of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Jianpeng LiuDivision of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Zhihao ZhangDivision of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Xizhi YuDivision of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Junjie QianDepartment of Hepaticobiliarypancreatic and Minimally Invasive Surgery, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, China.
Limin DingDepartment of Hepatobiliary and Pancreatic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Qinchuan WuDepartment of Breast Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Zhe YangDepartment of Hepatobiliary and Pancreatic Surgery, Shulan (Hangzhou) Hospital Affiliated to Zhejiang Shuren University Shulan International Medical College, Hangzhou, China.
Xing-Yu LuoDepartment of Hepatobiliary and Pancreatic Surgery, Shulan (Hangzhou) Hospital Affiliated to Zhejiang Shuren University Shulan International Medical College, Hangzhou, China.
Xinjiang DingDivision of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Rong SuDivision of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Xiaobo YuDivision of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Yiting QiaoDivision of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.ORCID https://orcid.org/0000-0002-7518-4233
Shengyong YinDivision of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Haiyang XieDivision of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.ORCID https://orcid.org/0000-0002-6913-9284
Lin ZhouDivision of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Yuanxing LiuDivision of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Shusen ZhengDivision of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.ORCID https://orcid.org/0000-0002-0936-6223

Funding

Hainan Province Science and Technology Special Fund ZDYF2025LCLH012Key R&D Program of China 2023YFC2306800Key Research and Development Project of Zhejiang Province 2024C03149National Natural Science Foundation of China 82172681National Natural Science Foundation of China 82470690Noncommunicable Chronic Diseases-National Science and Technology Major Project 2025ZD0552400Noncommunicable Chronic Diseases-National Science and Technology Major Project 2025ZD0552401Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences 2023-PT320-02Research Project of Jinan Microecological Biomedicine Shandong Laboratory JNL-2025007B
6 · The paper itself

Abstract

Patients with advanced hepatocellular carcinoma (HCC) have a poor prognosis and few effective treatments. The highly immunosuppressive tumor microenvironment and multifaceted immune escape mechanisms in HCC profoundly restrict the clinical efficacy of immune checkpoint inhibitors. Phosphoglycerate kinase 1 (PGK1) is established as an oncogenic driver in malignant tumor progression. However, its role in modulating tumor immunity remains elusive. This study found that HCC cell-intrinsic PGK1 contributed to tumor progression through inhibiting CD8

Indexed as

Carcinoma, HepatocellularCD8-Positive T-LymphocytesChemokine CCL2Liver NeoplasmsPhosphoglycerate KinaseReceptors, CCR2Tumor-Associated MacrophagesAnimalsCell Line, TumorHumansMaleMiceTumor MicroenvironmentCCL2 protein, humanCCR2 protein, humanChemokine CCL2PGK1 protein, humanPhosphoglycerate KinaseReceptors, CCR2CCL2CD8+ T cellhepatocellular carcinomaPGK1tumor‐associated macrophages

Identifiers

PMID42183839
PMCPMC13336124

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.